Predictive Algorithms To Revolutionize Clinical Trials
EXCITING NEWS! Hope NOW for ALS has been busy this year meeting with the FDA, researchers, and bio/pharma companies to promote a methodology for faster, less expensive, more accurate, and more humane trials. Specifically, we have been advocating the use of predictive algorithms that can reduce or eliminate the need for a placebo arm, and reduce the number of patients necessary to achieve the FDA’s required measure of statistical significance (p < 0.05). This will result in faster delivery of promising treatments.
This week Origent Data Sciences and Cytokinetics announced their collaboration for the Phase 3 trial of Tirasemtiv (VITALITY-ALS). Hope NOW for ALS played an important role in brokering this partnership and encouraging the ALS Association to provide grant funding. This collaboration represents a vital step forward in how ALS clinical trials are conducted and hastens efforts to find effective treatments. Thank you for your continued support!
Read the announcement here: https://globenewswire.com/news-release/2016/12/07/895765/0/en/Origent-Data-Sciences-and-Cytokinetics-Present-Analyses-Demonstrating-Baseline-Data-Predict-Measures-of-Vital-Capacity-in-Patients-With-ALS.html